KYOTO-SEMICONDUCTOR
5.8.2021 07:02:10 CEST | Business Wire | Press release
Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, announced its collaboration with Semtech Corporation (Nasdaq: SMTC ), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms. Kyoto Semiconductor has chosen to pair their new KP-A avalanche photodiode*1 , KPDEA13C with Semtech’s GN1089 transimpedance amplifier*2 to enable long distance optical communication.
"The pairing of Semtech’s transimpedance amplifier GN1089 with Kyoto Semiconductor’s KPDEA13C was ideal to optimize the performance,” said Tsuneo Takahashi, Kyoto Semiconductor president and CEO. “Through the joint collaboration, the KPDEA13C now includes a fast response suitable for a variety of optical needs.”
Kyoto Semiconductor’s KPDEA13C is front side illuminated, highly sensitive and mounted on an interposer board for ease of assembly. Additionally, Kyoto Semiconductor’s KPDEA13C and Semtech’s GN1089 together offer unparalleled performance at high speed enabling 25Gbaud PAM4*3*4 applications.
"Semtech’s GN1089 is a high performance transimpedance amplifier enabling both 25Gbaud and 56Gbaud applications. Its high linearity and low noise are features that were a perfect fit for the Kyoto Semiconductor, KPDEA13C,” said Timothy Vang, vice president, marketing and applications for Semtech’s Signal Integrity Products Group. “This collaboration with Kyoto Semiconductor showcases the outstanding quality of our solutions for high speed optical communications.”
Sample shipments of KP-A avalanche photodiode, KPDEA13C is scheduled to begin on August 31, 2021, and mass production is expected to start on December 27, 2021.
For evaluation report, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/news/2025/
- English: https://www.kyosemi.co.jp/en/news/1058/
For product datasheet, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/mgt/wp-content/uploads/2021/08/kpdea13c_jp.pdf
- English: https://www.kyosemi.co.jp/en/mgt/wp-content/uploads/2021/08/kpdea13c_en.pdf
For information on Semtech’s GN1089, please visit www.semtech.com/products/signal-integrity/transimpedance-amplifiers/gn1089
*1 Avalanche Photodiode
: Semiconductor Photodiode with photocurrent amplification by applying reverse bias voltage. This photocurrent amplification produces much more current than standard Photodiode. It is useful in the application where the high sensitivity is required.
*2 Transimpedance amplifier
: The circuit or device that convert a current from Photodiode to voltage.
*3 PAM4 (Pulse Amplitude Modulation 4-level)
: A technique of modulation. It uses four voltage levels to represent two bits logic, 00, 01, 10, and 11, against the traditional NRZ modulation uses two voltage levels to represents 1 bit logic, 0 and 1.
*4 25Gbaud PAM4
: PAM4 signal at 25Gbaud modulation speed. It achieves 2 times transmission speed compared with traditional 25Gbaud NRZ signal. i.e., 25Gbaud PAM4 achieves 50Gbps, against 25Gbaud NRZ achieves 25Gbps.
About Semtech’s Optical Products
Semtech’s optical networking product platforms provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure and passive optical network/Fiber to the X (FTTX) markets. For more information, visit https://www.semtech.com/products/signal-integrity
.
About Semtech
Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the NASDAQ Global Select Market under the symbol SMTC. For more information, visit http://www.semtech.com
.
About Kyoto Semiconductor
Kyoto Semiconductor was founded in Kyoto in 1980 as a specialized manufacturer of optical semiconductors. Based on our unique packaging technology, we manufacture semiconductors for optical communications and sensors, which boast high performance and high accuracy, at our own base in Japan with an integrated system from front-end to back-end processes, and supply them to customers around the world. Kyoto Semiconductor is a leader in optical device solutions with Japanese quality manufacturing, leveraging world-class technology. For more information, please. visit https://www.kyosemi.co.jp
.
*Semtech, the Semtech logo are registered trademarks or service marks of Semtech Corporation or its affiliates.
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication. Subject to change without notice. Please understand in advance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005473/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
